← 返回专利悬崖列表
CAS 168421-78-1
(1S,4S,5S,7R,10S,11R,12S,16S,19R)-4,19,21,21-tetramethyl-2-methylidene-14-oxo-5-[(triethylsilyl)oxy]-8,13,15,20-tetraoxahexacyclo[14.4.1.0(1,19).0(4,11).0(7,10).0(12,16)]henicosan-10-yl acetate
登记编号：(XIX)101438-18-b
应用背景（按来源药适应症）
乳腺癌Paclitaxel/Encequidar mesylate腺癌Paclitaxel/Encequidar mesylate血管肉瘤Paclitaxel/Encequidar mesylate实体瘤Paclitaxel/Encequidar mesylate
来源药（使用该中间体的合成路线）
| 品种 | 梯队 | 到期年 |
|---|---|---|
| Paclitaxel/Encequidar mesylatePaclitaxel/Encequidar mesylate | Tier C · 观察 / 贸易 | - |
合成路线中的位置（上下游链）
按路线登记顺序排列，左→右为合成方向；高亮为当前 CAS，其余可点击跳转对应档案。
(1S,4S,5S,7R,10S,11R,12S,16S,19R)-4,19,21,21-tetramethyl-2-methylidene-14-oxo-5-[(triethylsilyl)oxy]-8,13,15,20-tetraoxahexacyclo[14.4.1.0(1,19).0(4,11).0(7,10).0(12,16)]henicosan-10-yl acetate→(1S,4S,5S,7R,10S,11R,12S,16S,19R)-10-(benzyloxy)-4,19,21,21-tetramethyl-2-methylidene-5-[(triethylsilyl)oxy]-8,13,15,20-tetraoxahexacyclo[14.4.1.0(1,19).0(4,11).0(7,10).0(12,16)]henicosan-14-one→(1S,4S,5S,7R,10S,11R,12S,13S,16R)-10-(acetyloxy)-13-hydroxy-4,16,18,18-tetramethyl-2-methylidene-5-[(triethylsilyl)oxy]-8,17-dioxapentacyclo[11.4.1.0(1,16).0(4,11).0(7,10)]octadecan-12-yl benzoate→(1S,4S,5S,7R,10S,11R,12S,13S,16R)-10-(acetyloxy)-13-hydroxy-4,16,18,18-tetramethyl-2-oxo-5-[(triethylsilyl)oxy]-8,17-dioxapentacyclo[11.4.1.0(1,16).0(4,11).0(7,10)]octadecan-12-yl benzoate→(1S,2S,3R,4S,7R,9S,10S,12R)-4,12-bis(acetyloxy)-1-hydroxy-10,14,17,17-tetramethyl-11-oxo-9-[(triethylsilyl)oxy]-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate→(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-Bis(acetyloxy)-1,15-dihydroxy-10,14,17,17-tetramethyl-11-oxo-9-[(triethylsilyl)oxy]-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate→(2alpha,5beta,7beta,10beta,13alpha)-4,10-Bis(acetyloxy)-1,7,13-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
本站可供应的对应中间体
目录暂未收录该靶点的在售中间体 —— 可直接发起询价，需求会进入撮合池。
本页为中间体 CAS 注册档案：同 CAS 的多条路线登记已合并；后续供应商报价与买方需求以该 CAS 为主键撮合。